161 related articles for article (PubMed ID: 24289605)
1. No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.
Camargo EA; da Silva GN; Gobette CP; Marcondes JP; Salvadori DM
Asian Pac J Cancer Prev; 2013; 14(10):5941-8. PubMed ID: 24289605
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.
da Silva GN; de Castro Marcondes JP; de Camargo EA; da Silva Passos Júnior GA; Sakamoto-Hojo ET; Salvadori DM
Exp Biol Med (Maywood); 2010 Jul; 235(7):814-24. PubMed ID: 20558835
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.
da Silva GN; Filoni LT; Salvadori MC; Salvadori DMF
Pathol Oncol Res; 2018 Apr; 24(2):407-417. PubMed ID: 28577130
[TBL] [Abstract][Full Text] [Related]
4. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
Meng CF; Dai DQ; Guo KJ
Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma.
Su Y; Yin L; Liu R; Sheng J; Yang M; Wang Y; Pan E; Guo W; Pu Y; Zhang J; Liang G
Med Oncol; 2014 Feb; 31(2):784. PubMed ID: 24366688
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
[TBL] [Abstract][Full Text] [Related]
8. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
[TBL] [Abstract][Full Text] [Related]
9. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence.
Lee KH; Lee JS; Nam JH; Choi C; Lee MC; Park CS; Juhng SW; Lee JH
Langenbecks Arch Surg; 2011 Oct; 396(7):1017-26. PubMed ID: 21706233
[TBL] [Abstract][Full Text] [Related]
11. Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
Zhang H; Zhang S; Cui J; Zhang A; Shen L; Yu H
Aust N Z J Obstet Gynaecol; 2008 Oct; 48(5):505-9. PubMed ID: 19032668
[TBL] [Abstract][Full Text] [Related]
12. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients.
Scartozzi M; Franciosi V; Campanini N; Benedetti G; Barbieri F; Rossi G; Berardi R; Camisa R; Silva RR; Santinelli A; Ardizzoni A; Crinò L; Rindi G; Cascinu S
Lung Cancer; 2006 Jul; 53(1):103-9. PubMed ID: 16716446
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
Nordentoft I; Dyrskjøt L; Bødker JS; Wild PJ; Hartmann A; Bertz S; Lehmann J; Orntoft TF; Birkenkamp-Demtroder K
BMC Cancer; 2011 Apr; 11():135. PubMed ID: 21489314
[TBL] [Abstract][Full Text] [Related]
14. MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.
da Silva GN; de Camargo EA; Sávio AL; Salvadori DM
Mol Biol Rep; 2014 Jul; 41(7):4613-21. PubMed ID: 24652204
[TBL] [Abstract][Full Text] [Related]
15. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on P16, hMLH1 and MGMT genes and DNA methylation in human gastric cancer cells].
Meng CF; Zhu XJ; Dai DQ; Peng G
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep; 12(5):494-7. PubMed ID: 19742343
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
Wu F; Lu M; Qu L; Li DQ; Hu CH
Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
[TBL] [Abstract][Full Text] [Related]
17. Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.
da Silva GN; de Camargo EA; Salvadori DM
Mol Biol Rep; 2012 Dec; 39(12):10373-82. PubMed ID: 23053941
[TBL] [Abstract][Full Text] [Related]
18. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
Strathdee G; MacKean MJ; Illand M; Brown R
Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
[TBL] [Abstract][Full Text] [Related]
19. The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells.
Rose M; Noetzel E; Kistermann J; Eschenbruch J; Rushrush S; Gan L; Knüchel R; Gaisa NT; Dahl E
Cells; 2021 Apr; 10(5):. PubMed ID: 33924987
[TBL] [Abstract][Full Text] [Related]
20. Genetic analysis of hMLH1 in transitional cell carcinoma of the urinary tract: promoter methylation or mutation.
Furihata M; Takeuchi T; Ohtsuki Y; Terao N; Kuwahara M; Shuin T
J Urol; 2001 May; 165(5):1760-4. PubMed ID: 11342971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
